Affordable Access

Access to the full text

Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics

Authors
  • Yu, Yanke1
  • DuBois, Steven G.2
  • Wetmore, Cynthia3
  • Khosravan, Reza1
  • 1 Pfizer Inc., La Jolla, California, USA , La Jolla (United States)
  • 2 Harvard Medical School, Boston, Massachussetts, USA , Boston (United States)
  • 3 University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA , Phoenix (United States)
Type
Published Article
Journal
The AAPS Journal
Publisher
American Association of Pharmaceutical Scientists
Publication Date
Jan 23, 2020
Volume
22
Issue
2
Identifiers
DOI: 10.1208/s12248-020-0423-x
Source
Springer Nature
Keywords
License
Yellow

Abstract

Using physiologically based pharmacokinetic (PBPK) modeling and simulations, this study estimated the exposure of sunitinib and its active metabolite SU012662 in pediatric patients. A PBPK simulator, SimCYP, was used to develop and validate the pharmacokinetic models. Model development employed a combined “bottom–up” and “top–down” approach to fully utilize the available in vitro or in silico experimental data and in vivo observed clinical data. First, the PBPK model for sunitinib was established, then the cytochrome P450 3A4–mediated metabolism of sunitinib was used as the input for SU012662. PBPK models were validated using pharmacokinetics of sunitinib and SU012662 from one study in adult patients with solid tumors and three clinical trials in pediatric patients with solid or gastrointestinal stromal tumors. The models were further used to predict the exposure of sunitinib and SU012662 by pediatric age groups. The PBPK models for sunitinib and SU012662 developed based on pharmacokinetic characteristics in adults successfully predicted the observed in vivo pharmacokinetics of sunitinib and SU012662 in both adults and pediatric patients. Based on the SimCYP model predictions, a daily dose of 20 mg/m2 will produce sunitinib and SU012662 total exposures in pediatric patients similar to those in adults with gastrointestinal stromal tumor treated with a clinical dose of 50 mg once daily.

Report this publication

Statistics

Seen <100 times